Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Market Closed 05-22 16:00:00 EDT

0.3099

-0.0231

-6.94%

盘后0.3330

+0.0231+7.45%

19:59 EDT

High0.3700	Low0.3092	Vol11.02M
Open0.3501	D1 Closing0.3330	Amplitude18.26%
Mkt Cap37.50M	Tradable Cap32.54M	Total Shares121.00M
T/O3.64M	T/O Rate10.49%	Tradable Shares105.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.3099,"timestamp":1779480000000,"preClose":0.333,"halted":0,"volume":11015036,"hourTrading":{"tag":"盘后","latestPrice":0.333,"preClose":0.3099,"latestTime":"19:59 EDT","volume":2712294,"amount":851827.089952,"timestamp":1779494390149,"change":0.0231,"changeRate":0.07454,"amplitude":0.180703},"delay":0,"changeRate":-0.0693693693693694,"floatShares":105000000,"shares":121000000,"eps":-1.083111,"marketStatus":"Market Closed","change":-0.0231,"latestTime":"05-22 16:00:00 EDT","open":0.3501,"high":0.37,"low":0.3092,"amount":3642488.0134973596,"amplitude":0.182583,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.083111,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.333,"preHourTrading":{"tag":"盘前","latestPrice":0.3482,"preClose":0.333,"latestTime":"09:29 EDT","volume":288615,"amount":99554.2577808,"timestamp":1779456581729,"change":0.0152,"changeRate":0.045646,"amplitude":0.081982},"postHourTrading":{"tag":"盘后","latestPrice":0.333,"preClose":0.3099,"latestTime":"19:59 EDT","volume":2712294,"amount":851827.089952,"timestamp":1779494390149,"change":0.0231,"changeRate":0.07454,"amplitude":0.180703},"volumeRatio":1.629621,"impliedVol":0.6383,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2636022747","title":"Outlook Therapeutics Inc : Btig Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022747?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101146,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635902058","title":"Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635902058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635902058?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878851,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryOutlook Therapeutics Inc OTLK.OQ reported a quarterly adjusted loss of 16 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S25K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635377040","title":"Outlook Therapeutics Q2 adjusted EPS misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2635377040","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635377040?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:17","pubTimestamp":1778876260,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Q2 adjusted EPS misses analyst expectationsOverviewUS biopharmaceutical firm's fiscal Q2 adjusted EPS missed analyst expectationsUnit sales of LYTENAVA in Europe fell 10% quarter-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S11V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635626037","title":"Outlook Therapeutics Q2 Adjusted EPS USD -0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2635626037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635626037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:06","pubTimestamp":1778875564,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX666F6A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635663037","title":"Outlook Therapeutics Inc - Completes FDA Dispute Resolution Meeting for Ons-5010; Decision Expected in May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635663037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635663037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA6LMRH9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037688","title":"Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037688?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA6LMRH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751077","title":"BRIEF-Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751077","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751077?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:38","pubTimestamp":1778711888,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC FilingMay 13  - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS INC - ENTERS ATM OFFERING AGREEMENT WITH H.C. WAINWRIGHT FOR UP TO $100 MILLION - SEC FILINGOUTLOOK THERAPEUTICS INC - TERMINATES ATM SALES AGREEMENT WITH BTIG EFFECTIVE MAY 12, 2026 - SEC FILINGSource text: [ID:n0001104659-26-060305]Further company coverage: OTLK.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nFWN41Q1NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2635552497","title":"Outlook Therapeutics Inc - Enters Atm Offering Agreement With H.c. Wainwright for up to $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635552497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635552497?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:42","pubTimestamp":1778704923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nFWN41Q1NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635575512","title":"Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2635575512","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635575512?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:37","pubTimestamp":1778704636,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics entered an at-the-market offering agreement with H.C. Wainwright to sell up to USD 100 million of common stock.H.C. Wainwright will act as sales agent or principal for sales on Nasdaq or in privately negotiated transactions at prevailing market prices.Sales agent commission set at 3% of gross proceeds; company also agreed to reimburse certain legal fees.Cash and cash equivalents totaled about USD 7.7 million as of March 31, 2026, excluding USD 4.5 million of net proceeds from an April 2026 registered direct equity offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8qDRx0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285976","title":"Outlook Therapeutics Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285976","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285976?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:37","pubTimestamp":1778499427,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc  expected to post a loss of12cents a share - Earnings Preview Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to  show a rise in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O11D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629868657","title":"Outlook Therapeutics closes USD 5 million registered direct offering at USD 0.31/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629868657","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629868657?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:14","pubTimestamp":1776975246,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics closed a registered direct offering of 16,129,033 common shares at USD 0.31 per share, raising about USD 5 million gross.Concurrent private placement issued unregistered warrants for up to 16,129,033 shares at USD 0.31 exercise price.Warrants become exercisable following stockholder approval, with expiry five years from first exercisability.Company also repriced investor warrants covering 2,142,854 shares to USD 0.31 from USD 2.26.Net proceeds earmarked primarily for working capital, general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLb5g8qd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","OTLK","SG9999014021.USD","IE00BN0W2V16.EUR","NDAQ","BK4139","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629850202","title":"Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629850202","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629850202?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:05","pubTimestamp":1776974700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., April 23, 2026  -- Outlook Therapeutics, Inc.  , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 16,129,033 shares of its common stock at an offering price of $0.31 per share of common stock. Additionally, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 16,129,033 shares of common stock at an exercise price of $0.31 per share. The unregistered warrants will become exercisable on the later of  the date of stockholder approval of the issuance of the shares underlying the warrants and  the effective date of an amendment to the Company's certificate of incorporation to increase the authorized shares of the Company and will expire five years following the later of  the date th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OTLK","BK4585","LENZ","BK4139","TM","BK4588","BK4604","BK4555","BK4539","BK4099","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629040747","title":"Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629040747","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629040747?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:29","pubTimestamp":1776868193,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16.129M shares o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-to-sell-16-129m-shares-at-31c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-to-sell-16-129m-shares-at-31c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049983","title":"Outlook Therapeutics prices 16,129,033-share registered direct offering at USD 0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049983","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049983?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:36","pubTimestamp":1776861372,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics priced a USD 5 million registered direct offering at USD 0.31 per share.Deal covers 16,129,033 common shares or pre-funded warrants in lieu of shares.Concurrent private placement includes unregistered warrants for up to 16,129,033 shares at USD 0.31 exercise price.Net proceeds earmarked for working capital, general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLbkWF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049833","title":"Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049833?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA2MHBTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629306379","title":"Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2629306379","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629306379?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:16","pubTimestamp":1776806180,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics ( ($OTLK) ) has shared an announcement. On April 21, 2026, Outlook Therapeutics announced that it had completed a Federal Disp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-advances-fda-dispute-on-wet-amd-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-advances-fda-dispute-on-wet-amd-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4573","BK4543","BK4605","LU2458330169.SGD","LU0274383776.USD","LU1242518931.SGD","AMYY","BK4539","LU0823421416.USD","AMDU","LU0390134368.USD","LU0081259029.USD","LU2860962120.EUR","BK4512","LU1880398554.USD","LU2089985449.USD","LU0109392836.USD","LU1923623000.USD","BK4532","LU1988902786.USD","AMDG","LU0823434740.USD","LU1316542783.SGD","LU0127658192.USD","IE00B5949003.HKD","LU1951200564.SGD","BK4588","BK4566","IE0009356076.USD","BK4554","AMDW","BK4529","BK4141","LU2360106780.USD","LU0056508442.USD","LU0642271901.SGD","LU2264538146.SGD","AMUU","AMDD","DAMD","TLT","LU2098885051.SGD","LU0082616367.USD","LU2054465674.USD","IE0004445239.USD","LU2355687059.USD","LU0719512351.SGD","LU2250418816.HKD","LU0198837287.USD","LU0823434583.USD","BK4139","AMDL","AMDY","LU1303367103.USD","TMF","LU1880398471.USD","LU1989764664.SGD","LU1803068979.SGD","LU1861559042.SGD","LU1951198990.SGD","IE00BMPRXR70.SGD","LU1852331112.SGD","TLTW","LU0823421333.USD","BK4612","LU1242518857.USD","BK4575","LU0889565833.HKD","BK4614","BK4007","IE00BMPRXN33.USD","BK4585","LU0979878070.USD","LU1064131342.USD","LU2931357623.SGD","OTLK","LU2458330243.SGD","BK4534","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629452034","title":"BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629452034","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629452034?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:05","pubTimestamp":1776776759,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava (Bevacizumab-Vikg)Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS COMPLETES FEDERAL DI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA2Q4N2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603490","title":"Outlook Therapeutics Inc - Expects FDA Feedback in May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603490?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:05","pubTimestamp":1776776700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA2Q4N2Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625696863","title":"Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696863","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696863?lang=en_us&edition=fundamental","pubTime":"2026-04-08 02:11","pubTimestamp":1775585460,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/07/FDA-Warns-Check-Can-Codes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/07/FDA-Warns-Check-Can-Codes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/04/51688863/outlook-therapeutics-files-fda-resolution-request-after-rejection-for-vision-loss-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/04/51688863/outlook-therapeutics-files-fda-resolution-request-after-rejection-for-vision-loss-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","BK4530","LU1815336091.USD","BK4139","CRL","FDRR","LU0029874061.USD","IE00BFMHRM44.USD","LU0390134368.USD","LU0128526141.USD","BK4588","BK4539","BK4121","BK4007","LABU","LU0757428866.USD","LENZ","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625955505","title":"Outlook Therapeutics submits formal dispute resolution request to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625955505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625955505?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:19","pubTimestamp":1775567943,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it submitted a formal dispute resolution request to the FDA as a follow-up to its recent Type A meeting ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-submits-formal-dispute-resolution-request-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-submits-formal-dispute-resolution-request-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","LABU","OTLK","BK4007","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.3586},{"period":"1month","weight":0.0679},{"period":"3month","weight":-0.2498},{"period":"6month","weight":-0.8352},{"period":"1year","weight":-0.811},{"period":"ytd","weight":-0.8039}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.162721},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}